<p id="hl0000056" class="ng-scope">We read with interest the article by Sawalha et al. in Cardiovascular Revascularization Medicine on ‘Systematic review of COVID-19 related myocarditis: insights on management and outcome’ [<span> </span><button class="j-inline-reference inline-reference" data-refid="bb0005" id="refInSitubb0005">1</button><span> </span>].</p> <p id="hl0000058" class="ng-scope">Coronavirus disease 2019 (COVID-19), which started at the end of 2019 and spread rapidly, is observed in primary and secondary cardiac involvement in addition to resistant pneumonia, respiratory failure. Although the exact mechanism of cardiac involvement in COVID-19 is not known, one of the possible mechanisms is that the cardiac involvement is mediated by angiotensin converting enzyme-2 (ACE-2). Another possible potential cause is cytokine storm caused by T helper cells [<span> </span><button class="j-inline-reference inline-reference" data-refid="bb0010" id="refInSitubb0010">2</button><span> </span>,<span> </span><button class="j-inline-reference inline-reference" data-refid="bb0015" id="refInSitubb0015">3</button><span> </span>].</p>